Analysis
Sandoz Surges After Earnings as Biosimilar Demand Accelerates
Sandoz shares rise after Q2 sales grow 9% and biosimilar revenue jumps 22%. Analysis of patent expirations, margins, guidance and regulatory risks.
FINANCEMARKETS.INFO
FINANCEMARKETS.INFO
Sandoz shares rise after Q2 sales grow 9% and biosimilar revenue jumps 22%. Analysis of patent expirations, margins, guidance and regulatory risks.